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Background: Frontotemporal lobar degeneration (FTLD) is a heterogeneous group of neurodegenerative diseases
associated with personality changes and progressive dementia. Loss-of-function mutations in the growth factor
progranulin (GRN) cause autosomal dominant FTLD, but so far the pathomechanism of sporadic FTLD is unclear.
Results: We analyzed whether DNA methylation in the GRN core promoter restricts GRN expression and, thus,
might promote FTLD in the absence of GRN mutations. GRN expression in human lymphoblast cell lines is
negatively correlated with methylation at several CpG units within the GRN promoter. Chronic treatment with the
DNA methyltransferase inhibitor 5-aza-20-deoxycytidine (DAC) strongly induces GRN mRNA and protein levels. In a
reporter assay, CpG methylation blocks transcriptional activity of the GRN core promoter. In brains of FTLD patients
several CpG units in the GRN promoter are significantly hypermethylated compared to age-matched healthy
controls, Alzheimer and Parkinson patients. These CpG motifs are critical for GRN promoter activity in reporter
assays. Furthermore, DNA methyltransferase 3a (DNMT3a) is upregulated in FTLD patients and overexpression of
DNMT3a reduces GRN promoter activity and expression.
Conclusion: These data suggest that altered DNA methylation is a novel pathomechanism for FTLD that is
potentially amenable to targeted pharmacotherapy.
Keywords: 5-aza-20-deoxycytidine, DNA methylation, Epigenetics, FTLD, ProgranulinBackground
Frontotemporal Lobar Degeneration (FTLD) is the second
most common cause of presenile dementia in patients under
60 years of age and accounts for approximately 5 to 10% of
all patients suffering from dementia [1]. In FTLD, the
progressive neurodegeneration in the frontal and temporal
lobes is accompanied by proteinaceous intraneuronal inclu-
sions (reviewed in [2]), which allow for pathological stratifica-
tion into FTLD-subtypes: FTLD-tau and FTLD-FUS are
characterized by inclusions of microtubule associated protein
tau (MAPT) and fused in sarcoma (FUS), respectively,
whereas inclusions found in FTLD-TDP stain positive for
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distribution, and reproduction in any mediumWhile the majority of FTLD-cases occurs sporadically, 10 to
40% of FTLD patients have a positive family history with
hexanucleotide repeat expansions in the uncharacterized
gene C9ORF72 [5-7] or with mutations in the genes coding
for TDP-43 (TARDBP), valosin-containing protein (VCP)
[8,9], or in the growth factor progranulin (GRN) [10,11].
Approximately 70 FTLD-TDP-associated autosomal
dominant mutations in the GRN gene are known (http://
www.molgen.vib-ua.be/FTDMutations/). Pathogenic mu-
tations inhibit expression, secretion or activity of GRN
from one allele, resulting in haploinsufficiency [12]. In
neurons, GRN acts as a neurotrophic factor and is crucial
for proper morphology and connectivity [13]. Reduced
GRN levels presumably fail to sustain proper function and
survival in aged neurons and, thus, eventually lead to pro-
gressive neurodegeneration in FTLD [14-16].
Despite their germline mutation in the GRN gene, mu-
tation carriers for unclear reasons often show strikinglyMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Banzhaf-Strathmann et al. Acta Neuropathologica Communications 2013, 1:16 Page 2 of 15
http://www.actaneurocomms.org/content/1/1/16asymmetric cortical atrophy, which does not usually
occur in FTLD-tau or FTLD-TDP cases with C9ORF72
hexanucleotide repeat expansions [17,18]. It is tempting
to speculate that environmental factors and subsequent
epigenetic changes might contribute to unilateral disease
progression, as environmental factors have been shown
to modulate DNA methylation patterns in humans [19].
Histone deacetylase inhibitors boost GRN expression
levels [20], however, little is known about the (patho)
physiological mechanisms that govern GRN expression.
Next to histone modifications, DNA methylation is the
most widely studied mechanism of epigenetic gene regula-
tion. DNA hypermethylation at the 5′-position of cytosine
nucleotides that are followed by guanine nucleotides
(CpG dinucleotides) is associated with gene silencing
when occurring in normally unmethylated CpG-rich
promoter regions [21].
We tested the hypothesis that aberrant DNA methyla-
tion in the promoter region of GRN might contribute to
the pathogenesis of FTLD. Here, we show that GRN
expression is regulated by DNA methylation at several
CpG units in its promoter region, and we found that
GRN methylation is altered in FTLD patients compared
to healthy controls, possibly through altered expression
of DNA methyltransferases.
Results
GRN expression is inversely correlated to promoter
methylation
To address whether GRN expression is regulated by epi-
genetic mechanisms we analyzed the net level of GRN
secretion, which is composed of cellular GRN secretion,
re-uptake and degradation (called net secretion in the
following) in lymphoblast cell lines from 13 healthy indi-
viduals, two FTLD patients’ relatives, both carrying the
genetic variant V514M in the GRN gene (LCLs #14, 15),
and two FTLD patients with the genetic variants R298H
(LCL#16) and R432C (LCL #17) in the GRN gene. 24 h
after seeding identical cell numbers, the amount of net
secreted GRN varied significantly with over 100-fold
difference between the lowest and highest expressing cell
line (LCL #3 vs. LCL #12 (Figure 1a)). We hypothesize
that this large variation in GRN net secretion among dif-
ferent LCLs is partly due to differences in DNA methyla-
tion in the GRN promoter and other clonal effects.
To test if DNA methylation plays a role in the regula-
tion of GRN expression, genomic DNA from LCLs was
subjected to bisulfite treatment that specifically converts
all un-methylated cytosines to uracils, whereas methyl-
ated cytosines remain unaffected. We subsequently amp-
lified five amplicons (A-1 to A-5) by PCR, which were
subjected to quantitative DNA methylation analysis
using the MassARRAY platform as previously described
[22] (Figure 1b). As the sequence context in the GRNpromoter region is very GC rich, specific DNA amplifica-
tion is difficult especially after bisulfite conversion. PCR
amplification of other GRN promoter regions did not
result in specific PCR products suitable for DNA methyla-
tion analysis. However, analysis of amplicons A-1 to A-5
allowed us to quantify the DNA methylation levels at 29
CpG units, consisting of one CpG dinucleotide and rarely
of two CpG dinucleotides in case the two adjacent CpG
sites were not separated by a specific RNase A cleavage site
(pyrimidine nucleotides) (Additional file 1: Figure S1).
Average DNA methylation levels varied in the different
promoter/genomic regions ranging from 79% average
DNA methylation in the distal A-2 region to 7% in A-5 dir-
ectly upstream of the transcriptional start site (Figure 1c).
Next, we carried out linear regression analyses to
elucidate whether GRN DNA methylation levels of the
individual CpG units were inversely correlated to GRN
mRNA expression and GRN net secretion levels. As
depicted in Additional file 1: Table S3, we observed a
significant negative correlation for mRNA expression
and DNA methylation at CpG units 1, 6, 8, and 11.
Moreover, CpG unit 2 was significantly negatively corre-
lated to GRN net secretion (indicated with asterisks in
Figure 1b). To illustrate the significant negative correl-
ation, the mean of DNA methylation of these five signifi-
cant CpG units (1, 2, 6, 8 and 11) was plotted against
GRN mRNA expression (Figure 1d) and GRN net secre-
tion levels (Figure 1e). Genetic variations that have been
discussed to potentially alter GRN expression levels be-
fore (TMEM106b rs1990622 [23], GRN rs5848 [24] and
SORT1 rs646776 [25]), did neither correlate with differ-
ent GRN DNA methylation levels nor GRN mRNA/
protein expression (Additional file 1: Figure S2).
From these results we conclude that methylation levels
of specific CpG units in the GRN promoter 1–2 kb distal
of the transcriptional start site regulate GRN mRNA
expression and protein secretion in human cell lines.
5-aza-2′-deoxycytidine (DAC) treatment leads to
re-expression of GRN by reducing GRN promoter
methylation
Next, we asked whether inhibition of DNA methyl-
transferases (DNMTs) would lead to re-expression of GRN
mRNA by reducing DNA hypermethylation. We treated
LCL #3 and LCL #14 with 0.5 μM of the DNMT inhibitor
5-aza-2′-deoxycytidine (DAC) for 9 days, which leads to
progressive DNA demethylation upon DNA replication in
proliferating cells [26]. We analyzed DNA methylation in
one large amplicon (A-DAC) in the GRN promoter
region by MassARRAY (Figure 1b and Additional file 1:
Figure S1), covering 15 CpG units. As expected, in LCL
#3 the average DNA methylation level within A-DAC was
significantly reduced to 22% upon prolonged DAC treat-
ment compared to a stable methylation rate of 55% in
Figure 1 GRN expression in human lymphoblast cell lines is inversely correlated to its promoter methylation. (a) GRN net secretion was
measured by ELISA in LCLs derived from neurologically healthy individuals (LCL #1-13), unaffected relatives of FTLD patients (LCL #14, 15, highlighted
in blue) and FTLD-patients (LCL#16, 17, highlighted in red). n = 3, mean ± SEM. (b) Scheme of GRN promoter region. Red bars depict PCR-amplicons
analyzed for DNA methylation levels by MassARRAY. Blue bars indicate full length and short promoter region that was cloned into the pCpGL vector
for luciferase assays (compare Figure 3). White circles display CpG units in amplicons A-1 to A-5 and A-DAC quantified by MassARRAY. CpG units that
were not analyzed are not shown. Asterisks indicate significant correlation between GRN mRNA expression or GRN secretion and GRN methylation at
respective CpG unit (*p < 0.05, linear regression analysis, Benjamini Hochberg multiple testing and FDR correction, compare Additional file 1: Table S3).
(c) Average DNA methylation levels in amplicons A-1 to A-5 for individual LCLs are plotted. Mean ± SD. Color code as in (a). (d) Correlation between
GRN mRNA expression and average DNA methylation at CpG units 1, 2, 6, 8 and 11 is shown. GRN mRNA expression was quantified by qPCR and
normalized to PGK1 and GAPDH. Relative mRNA expression levels were plotted against average DNA methylation levels. Correlation between
parameters was quantified by linear regression analysis, r2 and p-values are given. Color code as in (a). (e) Correlation between GRN secretion and
average DNA methylation at CpG units 1, 2, 6, 8 and 11. GRN secretion was determined by ELISA and relative units (R.U.) were plotted against average
DNA methylation levels. Correlation between parameters was quantified by linear regression analysis, r2 and p-values are given. Color code as in (a).
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caused a significant reduction in GRN promoter methyla-
tion down to 16% after 9 days of treatment, while
untreated cells showed 40% DNA methylation (Figure 2a).
To test whether reduced DNA methylation enhances
GRN transcription, we analyzed GRN mRNA expression
in cells treated with DAC by qPCR. As shown in Figure 2b,
treatment with 0.5 μM DAC over 9 days led to a progres-
sive highly significant 11-fold increase in GRN mRNAFigure 2 The DNMT-inhibitor 5-aza-2′-deoxycytidine (DAC) reduces D
expression in LCLs. LCL #3 and #14 were treated daily with 0.5 μM DAC for 9
(compare Figure 1b) shows progressive demethylation in the GRN promoter reg
amplicon is shown. Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t-tes
to PGK1. GRN mRNA expression strongly increased, while the expression
ANOVA with Tukey’s Multiple Comparison test. (c) GRN secretion was qua
treatment of LCL #3 and LCL #14 with 0.5 μM DAC for 9 days significantly
while the secretion in mock treated control cells remained low. Mean ± S
Comparison test.expression in LCL #3. Similarly, LCL #14 also showed
highly significant 9-fold GRN mRNA induction after
9 days of DAC treatment, while the mRNA expression of
the commonly used housekeeping gene GAPDH remained
stable over time in both cell lines.
In parallel to GRN mRNA expression levels, GRN net
secretion in LCL #3 significantly increased 7-fold and
15-fold after 7 and 9 days of DAC treatment, respect-
ively (Figure 2c). In LCL #14, DAC treatment even ledNA methylation in the GRN promoter and increases GRN
days. (a) Quantitative DNA methylation analysis of amplicon A-DAC
ion. Average DNA methylation across all 15 CpG units in the A-DAC
t. (b) GRN mRNA expression levels were analyzed by qPCR and normalized
of GAPDH did not change. Mean ± SD, n = 3, **p < 0.01, ***p < 0.001,
ntified by ELISA and normalized to absolute cell number. Chronic
increased GRN protein secretion into the cell culture supernatant,
D, n = 3, **p < 0.01, ***p < 0.001, ANOVA with Tukey’s Multiple
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while GRN-secretion in control cells remained stable
over time (Figure 2c).
Enhanced GRN expression upon DNA demethylation
through chronic DAC treatment suggests that endogen-
ous methylation in the GRN promoter restricts GRN
expression.
GRN promoter activity is regulated by DNA methylation
at distinct CpG units
To directly analyze the effect of GRN promoter methyla-
tion on mRNA expression we used luciferase reporter as-
says. The GRN promoter region (from −2423 to +207 bp
relative to the transcriptional start site (Figure 1b)) was
cloned upstream of firefly luciferase into pCpGL, a vector
completely devoid of CpG motifs [27]. The putative GRN
promoter region enhanced luciferase activity 32-fold com-
pared to the empty vector upon transient transfection of
HEK 293FT cells. In vitro methylation using excess
enzyme to guarantee complete methylation of the reporter
plasmid prior to transfection, reduced GRN promoter ac-
tivity almost to background levels (Figure 3a). This further
supports our hypothesis that promoter methylation regu-
lates GRN expression. Since FTLD mainly manifests in
the cerebral cortex, we repeated these experiments in rat
cortical neurons transfected after five days in culture withFigure 3 DNA methylation inhibits GRN promoter activity at distinct C
containing the GRN core promoter region driving expression of firefly lucif
primary rat cortical neurons together with a Renilla luciferase expressing pl
construct with site specific mutations of the significant CpG units in amplic
amplicons A-1 and A-2 were transiently cotransfected into (c) HEK 293FT ce
luciferase expressing plasmid. Luciferase reporter activity was measured 48
luciferase activity was determined by normalizing firefly luciferase against R
control. Mean ± SEM, n ≥ 3. ***p < 0.001, Student’s t-test, sign. significant.the methylated and unmethylated GRN promoter con-
structs. In accordance to our findings in HEK 293FT cells,
the GRN promoter activity in primary neurons was almost
completely blocked by in vitro methylation in the lucifer-
ase reporter assay (Figure 3b).
Next, we tested whether the five CpG units 1, 2, 6, 8
and 11 that significantly correlated with reduced GRN
expression (see Figure 1) are crucial for maintaining full
GRN promoter activity. Because CpG methylation is
thought to block binding of transcription factors, we
mutated those five CpG dinucleotides to TpG dinucleo-
tides, which may also block binding of such transcription
factors. In addition, we cloned a short GRN promoter
construct which is devoid of amplicons A-1 and A-2, in
which the significant CpG units are located. Transient
transfection of the mutated GRN promoter construct into
HEK 293FT cells significantly reduced GRN promoter
activity by more than 40% compared to the wildtype GRN
promoter construct. Transfection of the truncated GRN
promoter led to a highly significantly reduced promoter
activity of more than 70% (Figure 3c). We confirmed these
findings by transfecting rat primary cortical neurons with
the mutated and short GRN promoter constructs, which
reduced the GRN promoter activity by more than 30%
and 20%, respectively, compared to the wildtype GRN
promoter construct (Figure 3d).pG units. In vitro methylated and unmethylated pCpGL plasmids
erase were transiently cotransfected into (a) HEK 293FT cells and (b)
asmid. The full length GRN promoter pCpGL plasmid, a GRN promoter
ons A-1 and A-2, and a short GRN promoter construct lacking
lls and (d) primary rat cortical neurons together with a Renilla
h (a + c, HEK 293FT) or 72 h (b + d, neurons) after transfection. Relative
enilla luciferase activity. The empty vector was used as negative
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methylation in the GRN core promoter region strongly
inhibits its transcriptional activity. Further, the presence
of the CpG units that showed a significant inverse cor-
relation between DNA methylation and GRN expression
are crucial for maintaining full GRN promoter activity.
The GRN promoter region is hypermethylated in brains
from FTLD patients
After having demonstrated that DNA methylation regu-
lates GRN promoter activity, we asked whether patients
who suffered from FTLD show aberrant GRN promoter
methylation in the brain. Therefore, we analyzed DNA
methylation in the frontal cortices of 20 FTLD patients
(pathological diagnosis FTLD-TDP [28,29], average age at
disease onset 60 ± 10.2 years, average age at death 66 ±
10.6 years), 8 AD patients (average age at onset: 69 ±
14.8 years, age at death: 80 ± 10.6 years), 8 PD patients
(average age at onset: 67 ± 16.2 years, age at death: 79 ±
8.4 years) and 15 healthy, age-matched controls (average
age at death 67 ± 10.1 years) (Table 1). We isolated gen-
omic DNA from human brain samples, performed bisul-
fite conversion, amplified five regions (A-1 through A-5)
upstream of the transcriptional start site of GRN (compare
Figure 1b), and subjected the PCR products to quantita-
tive methylation analysis. Similar to LCLs, the average
DNA methylation levels varied in the different amplicons
analyzed: Highest (and most variable) average DNA
methylation was observed in A3 (average 85%), whereas
CpG sites in the amplicon A-5 located directly upstream
of the transcriptional start site was much less methylated
(average 2%, Figure 4a).
By comparing average DNA methylation levels be-
tween all FTLD patients, AD patients, PD patients and
controls across the different amplicons, we observed a
slight, but highly significant increase in DNA methylation
from 57% to 62% in FTLD patients in amplicon A-1. DNA
methylation levels in amplicons A-2 to A-5 did not differ
significantly between FTLD, AD, PD patients and healthy
controls (Figure 4a).
As we had observed an inverse correlation between
GRN promoter methylation levels and GRN mRNA
expression and net secretion in LCLs (Figure 1d + e), we
next analyzed GRN mRNA expression levels in patient
and control brain by qPCR. Elevated DNA methylation
levels in amplicon A-1 were significantly correlated to
reduced GRN mRNA expression as depicted in Figure 4b,
indicating that epigenetic mechanisms may contribute to
the regulation of GRN expression in vivo. However, we
did not observe a significant difference in overall GRN
mRNA expression levels between FTLD patients and
AD or PD patients or healthy controls (Figure 4c).
Furthermore, SNPs in TMEM106b (rs1990622), GRN
(rs5848) and SORT1 (rs646776) did not correlate withdifferent GRN DNA methylation or GRN expression
levels (Additional file 1: Figure S3).
In summary, FTLD patients show altered GRN pro-
moter methylation suggesting that epigenetic mecha-
nisms may play a role in the regulation of GRN
expression in vivo. This finding is supported by a signifi-
cant inverse correlation of GRN mRNA expression and
DNA methylation levels in amplicon A-1 of the GRN
promoter in human brain samples.
DNMT levels are altered in FTLD patients
Cellular DNA methylation is orchestrated by three dis-
tinct DNA methyltransferases, DNMT1, DNMT3a and
DNMT3b, and aberrant expression of these DNMTs has
been causally linked to atypical DNA methylation levels
in human cancers [35]. Therefore, we analyzed DNMT
mRNA expression levels in the brain samples from
FTLD patients and healthy controls. While the expres-
sion levels of DNMT1 were unaffected (Figure 5a),
DNMT3a levels were significantly increased 8.4-fold in
FTLD patients compared to healthy controls (Figure 5b).
DNMT3b levels showed a trend towards increased ex-
pression, not reaching statistical significance (Figure 5c).
Therefore, we conclude that elevated DNMT3a expres-
sion may contribute to the aberrant DNA methylation
levels found in FTLD patients.
Overexpression of DNMT3a alters GRN promoter activity
in primary cortical neurons and reduces GRN mRNA
expression in LCLs
To elucidate whether altered DNMT expression levels can
modify GRN promoter activity, we transfected HEK 293FT
cells as well as primary cortical neurons with the pCpGL
vector containing the GRN promoter region (compare
Figure 1b) and a DNMT3a overexpression construct or the
respective empty vector control. DNMT3a overexpression
significantly reduced luciferase expression by more than
30% in HEK 293FT cells (Figure 1a) and by more than 50%
in primary cortical neurons (Figure 6a), suggesting reduced
GRN promoter activity upon methylation.
To further confirm that altered DNMT3a expression
levels can modify GRN expression directly, we analyzed
endogenous GRN mRNA expression after overexpression
of DNMT3a in LCL#3 and #14 using lentiviral expression
of DNMT3a. After five days of lentiviral transduction,
DNMT3a levels were strongly elevated in both cell lines
(Figure 6b). DNMT3a overexpression significantly re-
duced GRN mRNA expression by 71% in LCL#3 and by
44% in LCL#14 as quantified by qPCR (Figure 6c). In con-
trast, overexpression of DNMT1 did not alter GRN pro-
moter activity and GRN mRNA expression (Additional
file 1: Figure S4).
In summary, our data indicate that elevated DNMT3a
levels in FTLD lead to reduction in GRN expression,
Table 1 Pathological, clinical and genetic info of human brain samples used
























VIB Def. Control N.A. N.A. m N.A. 78.1 N.A. N.A. CT CC no AG yes
VIB Def. Control N.A. N.A. m N.A. 66.3 N.A. N.A. CT CC no AA yes
VIB Def. Control N.A. N.A. m N.A. 73.3 N.A. N.A. TT TC no AA yes
VIB Def. Control N.A. N.A. f N.A. 62.7 N.A. N.A. TT TC no AA yes
VIB Def. Control N.A. N.A. m N.A. 64.6 N.A. N.A. CT TT no AG yes
MRC Def. Control N.A. N.A. m N.A. 77 N.A. N.A. CC TC no AG yes
MRC Def. Control N.A. N.A. m N.A. 66 N.A. N.A. CT CC no AG yes
MRC Def. Control N.A. N.A. m N.A. 54 N.A. N.A. TT CC no AA yes
MRC Def. Control N.A. N.A. m N.A. 59 N.A. N.A. TT TC no AG yes
MRC Def. Control N.A. N.A. m N.A. 55 N.A. N.A. CC CC no AA yes
MRC Def. Control N.A. N.A. m N.A. 67 N.A. N.A. CT TC no AA yes
MRC Def. Control N.A. N.A. m N.A. 78 N.A. N.A. CT CC no AA yes
MRC Def. Control N.A. N.A. m N.A. 79 N.A. N.A. TT TC no AG yes
MRC Def. Control N.A. N.A. m N.A. 50 N.A. N.A. TT CC no AA yes
MRC Def. Control N.A. N.A. m N.A. 82 N.A. N.A. CT CC no AG yes
VIB FTLD-TDP MXD N.A. m 72 83 S no CT CC no AA yes
VIB FTLD-TDP B FTLD FTD m 47 50 F no CT CC no AG yes
VIB FTLD-TDP FTLD prob
AD
f 80 88 F no CT TT no AA yes
VIB FTLD-TDP B FTLD-ALS FTD-
ALS
m 59 62 S no CT CT no AG yes
VIB FTLD-TDP D FTLD FTD f 44 56 F-AD VCP Arg159His5 TT TC no AA yes
VIB FTLD-TDP D FTLD FTD m 63 68 F-AD VCP Arg159His5 CT TT no AA yes
VIB FTLD-TDP A FTLD N.A. f 62 68 F-AD GRN IVS1 +
5G > C6
CT TC no AA yes
VIB FTLD-TDP A FTLD N.A. f 58 63 F-AD GRN IVS1 +
5G > C6
TT TC no AG yes
VIB FTLD-TDP A FTLD N.A. m 57 62 F-AD GRN IVS1 +
5G > C6
CT TC no AG yes
VIB FTLD-TDP A FTLD FTD f 69 75 F-AD GRN IVS1 +
5G > C6
TT TC no AA yes
MRC FTLD-TDP B FTLD FTD +
MND
m 43 45 S no CT CC no AG yes
MRC FTLD-TDP B FTLD FTD +
MND
m 65 67 S no CC CC no AG yes
MRC FTLD-TDP B FTLD FTD +
MND
m 74 76 S no TT TC no AG no
MRC FTLD-TDP B FTLD FTD m 60 68 S no TT CC no AA yes
MRC FTLD-TDP B FTLD FTD m 45 51 S no CT TT no AG yes
MRC FTLD-TDP B FTLD FTD m 59 66 S no TT CC no AA yes
MRC FTLD-TDP B FTLD FTD +
MND
m 58 69 S no CC CC no AA yes
MRC FTLD-TDP B FTLD FTD m 58 66 S no CT CC no AG no
MRC FTLD-TDP B FTLD FTD/SD m 68 74 S no TT CC no AA yes
MRC FTLD-TDP B FTLD MND m N.A. 71 S N.A. TT TC no AA no
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Table 1 Pathological, clinical and genetic info of human brain samples used (Continued)
VIB AD-CAA Prob AD f 61 75 F APP -369C/G7 CT CC no AG yes
VIB AD Prob AD f - 85 S no CT TC no AA no
VIB AD Prob AD m 80 86 S no TT TC no AG yes
VIB AD Prob AD m 87 91 U no CC CC no AG yes
VIB AD Prob AD m 67 77 F no TT TC no AG yes
VIB AD Prob AD f 64 79 S no CT TT no AA no
VIB AD Poss AD m <84 87 S no CT CC no AA yes
VIB AD Prob AD f 50 57 F PSEN1 P264L8 TT TC no AA yes
MRC PD PD f 45 62 N.A. N.A. CC CC no AA yes
MRC PD Dementia f ~84 89 N.A. N.A. CT TC no AA yes
MRC PD PD f ~80 85 N.A. N.A. CC CC no AG yes
MRC PD PD m ? 73 N.A. N.A. CC CC no AG yes
MRC PD ? m ? 76 N.A. N.A. CC CC no AA yes
MRC PD PD f 76 80 N.A. N.A. CT TC no AG yes
MRC PD PD m 66 79 N.A. N.A. CT TC no AA yes
MRC PD PD?/AD m 82 84 N.A. N.A. CT TC no AA yes









AD Alzheimer’s disease, ALS amyothropic lateral sclerosis, APP amyloid precursor protein, CAA Cerebral Amyloid Angiopathy, F familial, F-AD familial autosomal
dominant, IVS splice donor site of intron 1 MND motorneuron disease, MRC Medical Research Council London Neurodegenerative Diseases Brain Bank, MXD mixed
dementia, N.A. not applicable, PD Parkinson’s disease, Prob probably, Poss possibly, S sporadic, SD semantic dementia, PSEN1 presenilin 1, U unknown, VIB VIB
Department of Molecular Genetics, Antwerp, Belgium.
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GRN promoter, which results in reduced GRN promoter
activity.
Discussion
In the present study we demonstrate that GRN expression
is regulated by DNA methylation in its core promoter
region. FTLD patients show aberrant DNA methylation
levels in the GRN promoter as well as altered expression
of DNA methyltransferase 3a, indicating that epigenetic
deregulation, particularly at the GRN promoter, may
contribute to FTLD.
To study epigenetic alterations in FTLD we used
lymphoblast cell lines (LCLs) derived from neurologically
healthy subjects and FTLD patients. By correlating GRN
mRNA expression and net secretion to DNA methylation
levels in LCLs, we detected a significant inverse correl-
ation in several CpG units in amplicon A-1 (Figure 1).
Strikingly, DNA methylation levels in amplicon A-1 in
brains of FTLD patients showed hypermethylation and an
inverse correlation to GRN mRNA expression as well
(Figure 4). This indicates that this region of the promoter
might play an important role in epigenetic regulation of
GRN expression. Historically, it was believed that DNAmethylation exclusively in so-called CpG islands, regions
with very high CpG density, is crucial for regulation of
gene expression. However more recently, DNA methyla-
tion in regions with intermediate CpG density upstream
of the CpG islands, so-called CpG island shores, has been
strongly linked to gene expression [36]. The GRN pro-
moter region is very CpG rich and it contains a CpG
island covered by amplicons A-3 to A-5 according to pre-
diction programs (e.g. http://dbcat.cgm.ntu.edu.tw/). Inter-
estingly, the CpG units that show an inverse correlation
with GRN expression are located within A-1 that display
lower CpG density, representing a CpG island shore [36].
This strongly points towards epigenetic regulation of GRN
expression in that particular region and supports our hy-
pothesis that aberrant GRN methylation in amplicon
A-1 regulates GRN expression in vivo.
Changes in DNA methylation levels have also been
shown for amyotrophic lateral sclerosis (ALS) and AD. A
genome-wide analysis of DNA methylation revealed
several candidate genes that are aberrantly methylated in
brain tissue of sporadic ALS patients that affect the ex-
pression of genes involved in calcium homeostasis, neuro-
transmission and oxidative stress [37]. In postmortem
brain DNA analyses of AD patients, the DNA methylation
Figure 4 GRN promoter DNA methylation is altered in FTLD-TDP patients. Genomic DNA from human frontal cortex samples was subjected
to bisulfite conversion to analyze DNA methylation in the GRN promoter by MassARRAY (See Figure 1b). (a) Box plots show average percentage
of DNA methylation in amplicons A-1 to A-5 comparing healthy controls (white), FTLD patients (red), AD patients (blue) and PD patients (yellow).
Whiskers depict 5–95 percentile, **p < 0.01, Kruskal Wallis test with Dunn’s Multiple Comparison Test. (b) Negative correlation of average DNA
methylation across amplicon A-1 to GRN mRNA expression. Correlation between parameters was quantified by linear regression analysis, r2 and
p-values are given. Color code as in (a). (c) Relative GRN mRNA expression levels in brains from controls, FTLD, AD and PD patients quantified by
qPCR and normalized to the housekeeping genes PGK1 and GAPDH. Mean ± SD.
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http://www.actaneurocomms.org/content/1/1/16status of telomerase reverse transcriptase (HTERT) was
elevated compared to age-matched healthy individuals,
however hypermethylation of HTERT was not accompan-
ied by reduced mRNA expression in this study [38]. These
findings are in accordance to our present data, as we
detected a small, but highly significant increase in GRN
promoter methylation, although we could not detect re-
duction in GRN mRNA expression. This discrepancy
might have several experimental and biological reasons:
First, genomic DNA itself and DNA methylation are far
more stable than RNA [39] and thus post-mortem methy-
lation levels more likely reflect the actual in vivo situation,
highlighting the importance of epigenetic studies for bio-
marker discovery. Second, cellular heterogeneity may im-
pair our analysis in the ground tissue from total frontal
cortex, as we could not test whether aberrant GRN pro-
moter methylation occurs only in a specific cell type or
globally. Microglia activation is a common inflammatory
response in FTLD brains (and other neurodegenerative
diseases) [40]. Inflammation leads to increased microglial
GRN expression [41], which may obscure a neuronal lossof GRN expression. A recent study demonstrated that
FTLD patients with GRN haploinsufficiency surprisingly
show elevated GRN mRNA expression levels in frontal
cortex tissue despite reduced GRN serum levels [42].
Thus, inflammatory responses are likely to have dramatic
effects on mRNA expression studies from the brain.
Nevertheless, a recent publication supports our hypothesis
that GRN expression is regulated by DNA methylation
levels in FTLD. Galimberti and colleagues analyzed GRN
promoter methylation at two CpG sites in close proximity
to the transcriptional start site, as well as mRNA and pro-
tein expression levels in blood cells and plasma from
FLTD patients [43]. Although they detected elevated
methylation at these sites using a semi-quantitative PCR-
based approach, they could not detect an inverse correl-
ation between DNA methylation and GRN expression
levels, suggesting that these CpG sites are not critical for
regulating GRN expression. In contrast, we measured ab-
solute quantities of DNA methylation across the 2500 nu-
cleotide GRN core promoter region by automated mass
spectrometry covering 29 CpG units in patient
Figure 5 In FTLD-TDP patients, DNMT3a mRNA expression
levels are altered. Relative mRNA expression levels of DNMT1
(a), DNMT3a (b) and DNMT3b (c) in brain samples quantified by
qPCR and normalized to the housekeeping genes PGK1 and GAPDH.
Mean ± SD, *p < 0.05, Kruskal Wallis test with Dunn’s Multiple
Comparison Test.
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significant inverse correlation for GRN expression and
DNA methylation further upstream in the CpG island
shore (amplicon A-1), which implies that this is the main
regulatory region of GRN expression. In exactly this re-
gion we also detected elevated DNA methylation levels in
brains from FTLD patients that were negatively correlatedto GRN mRNA expression levels, suggesting that altered
epigenetic marks may contribute to FTLD pathogenesis
(Figure 4).
In order to identify the mechanism of how altered
DNA methylation levels in the promoter region of GRN
are established, we analyzed mRNA expression of the
major DNA methyltransferases, DNMTs 1, 3a and 3b,
and found a significant induction of DNMT3a mRNA
expression in FTLD patients compared to controls.
DNMTs are essential for proper nervous system devel-
opment [44,45] and are expressed in the adult brain
including postmitotic neurons, where they play a role in
synaptic and behavioral plasticity [46]. Overexpressing
DNMT3a in LCLs significantly reduced GRN promoter
activity and resulted in significantly reduced GRN mRNA
expression levels (Figure 6), whereas overexpression of
DNMT1 did not have inhibitory effects on GRN promoter
activity and GRN mRNA expression (Additional file 1:
Figure S4). This finding is in line with the fact that
DNMT1 is the maintenance DNA methyltransferase
(during mitosis) while DNMT3a and 3b are de novo
methyltransferases and are thus crucial for adding new
methyl groups to CpG dinucleotides [47]. Thus, ele-
vated expression of DNMT3a in the cortices of FTLD
patients might add to neuronal vulnerability and cell
loss in addition to controlling GRN expression.
Epigenetic therapies using DNMT inhibitors and his-
tone deacetylase (HDAC) inhibitors have been approved
by the U.S. Food and Drug Administration (FDA) for can-
cer chemotherapy [48]. Recent evidence from cell culture
and animal studies suggests that HDAC inhibitors, such
as sodium butyrate or trichostatin A can improve memory
formation and cognition in models of neurodegenerative
diseases [49,50]. Thus, correcting epigenetic abnormalities
is a promising therapeutic strategy for neurodegenerative
diseases. Novel approaches towards treatment of FTLD
have attempted to pharmacologically induce GRN protein
levels [20,51]. Treatment of cells with the DNA-
demethylating drug DAC preferentially reactivates genes
silenced by de novo methylation. In our study, continued
DAC treatment led to a highly significant re-expression of
GRN in human lymphoblast cells (Figure 2). Thus,
targeting the DNA methylation machinery in FTLD might
be a potential strategy to elevate GRN levels and, hence,
offer therapeutic options for FTLD patients. Interestingly,
infusion of zebularine, a DNA methyltransferase inhibitor,
into mouse brain resulted in immediate DNA demethyla-
tion of several genes leading to enhanced transcription
[52]. In human and murine brain, GRN is predominantly
expressed in neurons and microglia [11,53]. We also
found a robust increase of GRN expression in the murine
microglia cell line BV-2 upon chronic DAC-treatment
(Additional file 1: Figure S5), suggesting that DAC-
treatment also elevates GRN in brain derived cells. As
Figure 6 Overexpression of DNMT3a alters GRN promoter activity in primary cortical neurons and reduces GRN mRNA expression in
LCLs. (a) pCpGL plasmid containing the GRN core promoter and a DNMT3a overexpression construct were transiently transfected in HEK 293FT
cells (left panel) and in rat primary cortical neurons (right panel). Relative luciferase activity was determined by normalizing firefly luciferase
against Renilla luciferase activity. Empty vectors were used as negative control. Firefly luciferase expression was significantly reduced upon
DNMT3a overexpression. Mean ± SEM, n ≥ 3. ***p < 0.001, ANOVA with Tukey’s Multiple Comparison test. (b) Lentiviral expression of DNMT3a in
LCLs #3 and #14. Overexpression was verified by qPCR five days after viral transduction. n = 5, mean ± SEM, *p < 0.05, Student’s t-test. (c) GRN
mRNA expression levels were significantly reduced in DNMT3a overexpressing LCLs as quantified by qPCR and normalized to PGK1 expression
levels. n = 5, mean ± SEM, *p < 0.05, Student’s t-test.
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peutics [54], treating FTLD and other neurodegenerative
disorders with DNA demethylating drugs and/or HDAC
inhibitors might be a promising future perspective [55].
Conclusion
In summary, we have demonstrated that DNA methyla-
tion in the GRN promoter region physiologically regu-
lates GRN expression. In brains from FTLD patients, the
promoter region of GRN is aberrantly methylated, whichmay be a novel risk factor for the development of FTLD.
Future studies will elucidate whether treatment with DNA
demethylating drugs not only restore adequate GRN
expression, but also delay or prevent FTLD progression.
Methods
Human derived material
The Ethical Committee of the University of Antwerp and
the Antwerp University Hospital approved collection of
biomaterials of patients and control individuals for clinical,
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erative brain diseases. EBV-transformed lymphoblast cell
lines from 15 neurologically healthy individuals and two
FTLD patients were provided by the Flanders-Belgian
biobank of the Neurodegenerative Brain Diseases group of
the VIB Department of Molecular Genetics (VIB DMG),
Antwerp, Belgium. Tissue from frontal cortex of 10 FTLD
patients and 5 neurologically healthy control individuals
was provided from the Antwerp Brain Bank of the Institute
Born-Bunge at the University of Antwerp, Antwerp,
Belgium. The FTLD patient group consisted of 4 patients
with FTLD-TDP brain pathology with unidentified genetic
cause, 4 patients with FTLD-TDP brain pathology due to a
GRN mutation [10], and 2 FTLD patients carrying a VCP
mutation [32]. Additionally, frontal cortex tissue from 10
sporadic FTLD-TDP patients with unknown genetic cause
and 10 neurologically healthy controls were obtained from
the MRC London Neurodegenerative Diseases Brain Bank,
part of the Brains for Dementia Research network (http://
www.brainsfordementiaresearch.org.uk/). The AD patient
group consisted of 6 patients with no known genetic cause
of disease, one patient carrying a mutation in the gene for
Amyloid Precursor Protein (APP 369-C/G) [33], and one
patient carrying a familial mutation in the Presenilin1
(PSEN1, P264L) gene [34]. The PD patient group consisted
of 8 patients without known genetic cause of disease
(Table 1).
For DNA and RNA extraction 30–50 mg of fresh-frozen
frontal cortex was ground in liquid nitrogen. DNA was iso-
lated using the DNeasy Blood & Tissue Kit (Qiagen) and
total RNA extraction was performed using the Ribopure
Kit (Ambion, Applied Biosystems) or using TRIzol®
(Invitrogen) and treated with DNase (Turbo DNase Kit;
Ambion, Applied Biosystems). The integrity and quality of
all human RNAs was verified by Agilent Bioanalyzer 2100
analysis. Due to different post-mortem delays, RNA quality
varied between brain samples. According to recent publica-
tions, an RNA integrity number of 3.5 was considered as
cutoff for subsequent qPCR analyses [56]. Samples with
poor melting curve quality were discarded.
SNP genotyping
The patients and control individuals obtained from the
VIB DMG biobank were genotyped for genetic variants
in TMEM106b rs1990622 [30,57], GRN rs5848 [31] and
SORT1 rs646776 (van der Zee et al. unpublished data).
LCLs and brain samples obtained from the MRC London
Neurodegenerative Diseases Brain Bank, part of the Brains
for Dementia Research network, were genotyped by
subjecting DNA to quantitative real time PCR using
Taqman probes (Life Technologies, TMEM106b rs1990622,
GRN rs5848) according to the manufacturer’s instructions.
Genetic variants in SORT1 rs646776 were analyzed by PCR
amplification (sense primer: CCAGAAGGCCCCACCGGGA, antisense primer: CCCGTGCAGCCTCTCCCACC)
and subsequent sequencing (GATC, Konstanz, Germany).
GGGGCC hexanucleotide repeat expansions in C9orf72
were assessed as described in [6,58].
Cell culture and drug treatment
HEK 293FT and microglia BV-2 cells were maintained in
DMEM Glutamax cell culture media (Life Technologies),
supplemented with 10% fetal calf serum (Sigma Aldrich)
and non-essential amino acids (Life Technologies). Epstein
Barr virus transformed lymphoblast cells [12,59] were
cultured in RPMI 1640 medium (Life Technologies),
supplemented with 10% fetal calf serum (Sigma Aldrich)
and glutamine (Life Technologies). 5 × 105 cells per ml
were seeded and treated with 0.5 μM (LCLs) or 0.13 μM
(BV-2) 5-aza-2′-deoxycytidine (DAC, Sigma Aldrich),
dissolved in DMSO. Due to the low half-life of DAC, the
cell culture media and DAC was replaced daily. After
treatment for 3, 5, 7 and 9 days, supernatant was collected,
cells were harvested and further analyzed.
DNA isolation
DNA was isolated from lymphoblast cell lines using the
DNeasy Blood & Tissue Kit (Qiagen) according to the
manufacturer’s instructions.
Quantitative methylation analysis MassARRAY
(Sequenom)
DNA methylation at individual CpG units was quantified
using the MassARRAY platform, as previously described
[22]. Briefly, bisulfite converted DNA (using the EZ DNA
methylation kit, Zymo Research) was PCR-amplified (for
primer information see Additional file 1: Table S1), in vitro
transcribed using T7 RNA polymerase, cleaved by RNase
A and subjected to matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (Sequenom).
Mass shifts of 16 Da introduced by the initial bisulfite con-
version led to distinct signal patterns for methylated and
non-methylated DNA templates, which allowed for proper
quantification of DNA methylation.
RNA isolation, reverse transcription and quantitative PCR
RNA from lymphoblast and microglia cell lines was
isolated with TRIzol® (Life Technologies) followed by
DNase digestion (Qiagen). cDNA synthesis was carried
out using the Taqman MicroRNA Reverse Transcription
Kit (Applied Biosystems) using random hexamer primers
(Sigma Aldrich). Quantitative Real Time PCR of human
and murine GRN (Hs00173570_m1, Mm01245914_g1,
Life Technologies) and PGK1 (Hs00943178_g1, Mm0043
5617_m1, Life Technologies) was performed using Taqman
microRNA mastermix following standard protocols. All
other genes were analyzed using the SsoFast Evagreen
Supermix (BioRad, for primer information see Additional
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normalized to the housekeeping genes PGK1 and/or
GAPDH. Relative mRNA abundance was calculated with
the ΔΔCt method.
GRN ELISA
The supernatant of lymphoblast cell lines was diluted
1:1 with PBS and analyzed by ELISA as described else-
where [51].
Isolation of primary rat cortical neurons, transfection and
luciferase assay
Primary cortical neurons were prepared from rats as de-
scribed previously [60]. The GRN promoter region (−2423
to +207 bp relative to transcriptional start site, for primers
see Additional file 1: Table S1) was cloned directly into the
CpG-free vector pCpGL and in vitro methylated using
recombinant DNA methyltransferase M.SssI (New England
Biolabs). The unmethylated control vector was obtained by
omitting S-adenosylmethionine from the M.SssI methyla-
tion reaction mix [27]. HEK 293FT cells and primary rat
cortical neurons (five days in culture) were transiently
transfected in 96-multiwell plates using 0.3 μl (HEK
293FT) or 0.25 μl (primary neurons) Lipofectamine 2000
(Life Technologies), 80 ng of reporter plasmid and 80 ng of
Renilla luciferase expression vector [60]. After 48 h (HEK
293FT) or 72 h (primary neurons), cells were assayed
for firefly and Renilla luciferase activity using the dual
luciferase reporter assay system (Promega).
Lentiviral transduction
For lentiviral overexpression of DNMT1 and 3a, the coding
sequences of DNMT1 and 3a were cloned into a lentiviral
vector under the control of the human ubiquitin C
promoter (for primers see Additional file 1: Table S1) [60].
Lymphoblast cells (5 × 105 cells/ml) were transduced and
harvested for RNA isolation five days later.
Statistics
Results are presented as mean ± standard deviation (SD)
or standard error (SEM) as indicated. For statistical evalu-
ation one-way ANOVA, Student’s t-test, Mann Whitney
U test or Kruskal Wallis test using the GraphPad Prism 5
Software was applied. Values of p < 0.05 were considered
as statistically significant. Benjamini Hochberg multiple
testing was carried out using an estimated false discovery
rate (FDR) of q = 0.25.
Additional file
Additional file 1: Supporting information.
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